Renaparin is under clinical development by Corline Biomedical and currently in Phase I for Delayed Graft Function (DGF). According to GlobalData, Phase I drugs for Delayed Graft Function (DGF) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Renaparin LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Renaparin overview
Renaparin is under development for the treatment of ischemia-reperfusion injury during kidney transplantation, delayed graft function and lung transplantation. The therapeutic drug candidate is administrated intravenously. The therapeutic candidate is formulated as solution. It is a macromolecular conjugate of heparin sodium on a polymer backbone.
Corline Biomedical overview
Corline Biomedical, formerly Corline Systems, is a manufacturer of heparin based solutions. It provides heparin based solutions to improve kidney transplantation, and applications in the field of regenerative medicine, among others. The company offers regenerative medicines such as cytoparin for cell therapy and diabetes type 1, and renaparin for kidney transplantation. Corline Biomedical provides CHC based on pre-assembled aggregates of heparin molecules. The company also provides surface coatings. It partners with medical device companies to improve blood and biocompatibility of medical device implants. Corline Biomedical is headquartered in Uppsala, Sweden.
For a complete picture of Renaparin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
